ENTRY       D11703                      Drug
NAME        Opinercept (INN)
SEQUENCE    LPAQVAFTPY APEPGSTCRL REYYDQTAQM CCSKCSPGQH AKVFCTKTSD TVCDSCEDST
            YTQLWNWVPE CLSCGSRCSS DQVETQACTR EQNRICTCRP GWYCALSKQE GCRLCAPLRK
            CRPGFGVARP GTETSDVVCK PCAPGTFSNT TSSTDICRPH QICNVVAIPG NASMDAVCTS
            TSPTRSMAPG AVHLPQPVST RSQHTQPTPE PSTAPSTSFL LPMGPSPPAE GSTGDEPKSC
            DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD
            GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK
            GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS
            DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK
            (Disulfide bridge: 18-31, 32-45, 35-53, 45-387, 56-71, 74-88, 78-96, 98-104, 112-121, 115-139, 142-157, 163-178, 240-240', 246-246', 249-249', 281-341)
  TYPE      Peptide
REMARK      ATC code: L04AB07
EFFICACY    Anti-inflammatory, Antirheumatic, TNF-alpha inhibitor
TARGET      TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156]
  PATHWAY   hsa04010(7124)  MAPK signaling pathway
            hsa04060(7124)  Cytokine-cytokine receptor interaction
            hsa04064(7124)  NF-kappa B signaling pathway
            hsa04350(7124)  TGF-beta signaling pathway
            hsa04668(7124)  TNF signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
                 L04AB07 Opinercept
                  D11703  Opinercept (INN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Tumor necrosis factors
                TNF (TNFA, TNFSF2)
                 D11703  Opinercept (INN)
DBLINKS     CAS: 2055118-96-0
            PubChem: 405226569
///
